NOX3 does not associate with MS incidence59 (P = 0.527, OR = 1.01) and to the best of our knowledge this is the first such association between a functional effect on ROS generation and the clinical response to therapeutic intervention in any autoimmune disease. This evidence concerns the gene NOX3 and myeloid sarcoma.